Search

Your search keyword '"Bahri, Meriem"' showing total 20 results
Start Over Author "Bahri, Meriem"
20 results on '"Bahri, Meriem"'

1. LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer

Author

Anstee, Joanne E., Feehan, Karen T., Opzoomer, James W., Dean, Isaac, Muller, Henrike P., Bahri, Meriem, Cheung, Tik Shing, Liakath-Ali, Kifayathullah, Liu, Ziyan, Choy, Desmond, Caron, Jonathan, Sosnowska, Dominika, Beatson, Richard, Muliaditan, Tamara, An, Zhengwen, Gillett, Cheryl E., Lan, Guocheng, Zou, Xiangang, Watt, Fiona M., Ng, Tony, Burchell, Joy M., Kordasti, Shahram, Withers, David R., Lawrence, Toby, and Arnold, James N.

Published
2023
Full Text
View/download PDF

4. LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer.

Author

Afd Pharmacology, Pharmacology, Anstee, Joanne E, Feehan, Karen T, Opzoomer, James W, Dean, Isaac, Muller, Henrike P, Bahri, Meriem, Cheung, Tik Shing, Liakath-Ali, Kifayathullah, Liu, Ziyan, Choy, Desmond, Caron, Jonathan, Sosnowska, Dominika, Beatson, Richard, Muliaditan, Tamara, An, Zhengwen, Gillett, Cheryl E, Lan, Guocheng, Zou, Xiangang, Watt, Fiona M, Ng, Tony, Burchell, Joy M, Kordasti, Shahram, Withers, David R, Lawrence, Toby, Arnold, James N, Afd Pharmacology, Pharmacology, Anstee, Joanne E, Feehan, Karen T, Opzoomer, James W, Dean, Isaac, Muller, Henrike P, Bahri, Meriem, Cheung, Tik Shing, Liakath-Ali, Kifayathullah, Liu, Ziyan, Choy, Desmond, Caron, Jonathan, Sosnowska, Dominika, Beatson, Richard, Muliaditan, Tamara, An, Zhengwen, Gillett, Cheryl E, Lan, Guocheng, Zou, Xiangang, Watt, Fiona M, Ng, Tony, Burchell, Joy M, Kordasti, Shahram, Withers, David R, Lawrence, Toby, and Arnold, James N

Published
2023

5. Perivascular macrophages collaborate to facilitate chemotherapy resistance in cancer

Author

Anstee, Joanne E., primary, Opzoomer, James W., additional, Dean, Isaac, additional, Muller, Henrike P., additional, Bahri, Meriem, additional, Liakath-Ali, Kifayathullah, additional, Liu, Ziyan, additional, Choy, Desmond, additional, Caron, Jonathan, additional, Sosnowska, Dominika, additional, Beatson, Richard, additional, Muliaditan, Tamara, additional, An, Zhengwen, additional, Gillett, Cheryl E., additional, Lan, Guocheng, additional, Zou, Xiangang, additional, Watt, Fiona M., additional, Ng, Tony, additional, Burchell, Joy M., additional, Kordasti, Shahram, additional, Withers, David R., additional, Lawrence, Toby, additional, and Arnold, James N., additional

Published
2022
Full Text
View/download PDF

6. LYVE-1 + Macrophages Form a Collaborative CCR5-Dependent Perivascular Niche That Influences Chemotherapy Responses in Cancer

Author

Anstee, Joanne E., primary, Opzoomer, James W., additional, Dean, Isaac, additional, Muller, Henrike P., additional, Bahri, Meriem, additional, Liakath-Ali, Kifayathullah, additional, Liu, Ziyan, additional, Choy, Desmond, additional, Caron, Jonathan, additional, Sosnowska, Dominika, additional, Beatson, Richard, additional, Muliaditan, Tamara, additional, An, Zhengwen, additional, Gillett, Cheryl E., additional, Lan, Guocheng, additional, Zou, Xiangang, additional, Watt, Fiona M., additional, Ng, Tony, additional, Burchell, Joy M., additional, Kordasti, Shahram, additional, Withers, David R., additional, Lawrence, Toby, additional, and Arnold, James N., additional

Published
2022
Full Text
View/download PDF

8. Impairing Temozolomide Resistance Driven by Glioma Stem-like Cells with adjuvant Immunotherapy Targeting O-acetyl GD2 Ganglioside

Author

Fleurence, Julien, Bahri, Meriem, Fougeray, Sophie, Faraj, Sébastien, Vermeulen, Sarah, Pinault, Émilie, Geraldo, Fanny, Oliver, Lisa, Véziers, Joëlle, Marquet, Pierre, Rabé, Marion, Gratas, Catherine, Vallette, François, Pecqueur, Claire, Paris, François, Birklé, Stéphane, Endothelium Radiobiology and Targeting (CRCINA-ÉQUIPE 14), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN), Biologie Intégrative Santé Chimie Environnement (BISCEm), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Regenerative Medicine and Skeleton research lab (RMeS), Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Plateforme 'Production de protéines recombinantes' (P2R - INSERM UMS016/CNRS UMS3556/UN FED4203), Structure fédérative de recherche François Bonamy (SFR François Bonamy), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN), Ostéo-articulaire - Tête et cou - Odontologie - Neurochirurgie - Neurotraumatologie [CHU Nantes] (Pôle hospitalo-universitaire PHU4 - OTONN), Centre hospitalier universitaire de Nantes (CHU Nantes), Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Laboratoire de Biologie des Cancers et de Théranostic [St Herblain, Nantes] (LabCT), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, and ANR-13-RPIB-0001,GANGSTEMAB,Thérapie des cellules souches tumorales avec des anticorps monclonaux humanisés anti-ganglioside(2013)

Subjects
brain cancer, cancer immunotherapy, oncology, [SDV.CAN]Life Sciences [q-bio]/Cancer, neoplasms, nervous system diseases
Abstract

JF and MB contributed equally to this work.; International audience; Stem cell chemo-resistance is still challenging the efficacy of the front-line temozolomide against glioblastoma. Novel therapies are urgently needed to fight those cells in order to control tumor relapse. Here, we report that anti-O-acetyl-GD2 adjuvant immunotherapy controls glioma stem-like cell-driven chemo-resistance. Using patient-derived glioblastoma cells we found that glioma stem-like cells over-expressed O-acetyl-GD2. As a result, monoclonal antibody 8B6 immunotherapy significantly increased temozolomide genotoxicity and tumor cell death in vitro by enhancing temozolomide tumor uptake. Furthermore, the combination therapy decreased the expression of the glioma stem-like cell markers CD133 and Nestin and compromised glioma stem-like cell self-renewal capabilities. When tested in vivo, adjuvant 8B6 immunotherapy prevented the extension of the temozolomide-resistant glioma stem-like cell pool within the tumor bulk in vivo and was more effective than the single agent therapies. This is the first report demonstrating that anti-O-acetyl-GD2 monoclonal antibody 8B6 targets glioblastoma in a manner that control temozolomide-resistance driven by glioma stem-like cells. Together our results offer a proof of concept for using anti-O-acetyl GD2 reagents in glioblastoma to develop more efficient combination therapies for malignant gliomas. This article is protected by copyright. All rights reserved.

Published
2019

10. Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Author

Fleurence, Julien, Fougeray, Sophie, Bahri, Meriem, Cochonneau, Denis, Clémenceau, Béatrice, Paris, François, Heczey, Andras, Birklé, Stéphane, Endothelium Radiobiology and Targeting (CRCINA-ÉQUIPE 14), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1), Texas Children’s Cancer Center [Houston, TX, USA], Baylor College of Medecine, The authors thank La Ligue Contre le Cancer for supporting Julien Fleurence’s and Meriem Bahri’s Ph. D. scholarship. This paper was written as a part of research project which received funding from the association Hubert Gouin—Enfance et Cancer., Bernardo, Elizabeth, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.

Published
2017

11. Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Author

Fleurence, Julien, Fougeray, Sophie, Bahri, Meriem, Cochonneau, Denis, Clémenceau, Béatrice, Paris, François, Heczey, Andras, and Birklé, Stéphane

Subjects
Article Subject
Abstract

Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.

Published
2017
Full Text
View/download PDF

12. Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside.

Author

Fleurence, Julien, Bahri, Meriem, Fougeray, Sophie, Faraj, Sébastien, Vermeulen, Sarah, Pinault, Emilie, Geraldo, Fanny, Oliver, Lisa, Véziers, Joëlle, Marquet, Pierre, Rabé, Marion, Gratas, Catherine, Vallette, François, Pecqueur, Claire, Paris, François, and Birklé, Stéphane

Subjects
GLIOBLASTOMA multiforme, CELL death, STEM cells, IMMUNOTHERAPY, MONOCLONAL antibodies, OLIGODENDROGLIOMAS
Abstract

Stem cell chemoresistance remains challenging the efficacy of the front‐line temozolomide against glioblastoma. Novel therapies are urgently needed to fight those cells in order to control tumor relapse. Here, we report that anti‐O‐acetyl‐GD2 adjuvant immunotherapy controls glioma stem‐like cell‐driven chemoresistance. Using patient‐derived glioblastoma cells, we found that glioma stem‐like cells overexpressed O‐acetyl‐GD2. As a result, monoclonal antibody 8B6 immunotherapy significantly increased temozolomide genotoxicity and tumor cell death in vitro by enhancing temozolomide tumor uptake. Furthermore, the combination therapy decreased the expression of the glioma stem‐like cell markers CD133 and Nestin and compromised glioma stem‐like cell self‐renewal capabilities. When tested in vivo, adjuvant 8B6 immunotherapy prevented the extension of the temozolomide‐resistant glioma stem‐like cell pool within the tumor bulk in vivo and was more effective than the single agent therapies. This is the first report demonstrating that anti‐O‐acetyl‐GD2 monoclonal antibody 8B6 targets glioblastoma in a manner that control temozolomide‐resistance driven by glioma stem‐like cells. Together our results offer a proof of concept for using anti‐O‐acetyl GD2 reagents in glioblastoma to develop more efficient combination therapies for malignant gliomas. What's new? Glioblastoma multiforme (GBM) is a complex malignancy harboring differentiated tumor‐bulk cells and self‐renewing GBM stem‐like cells (GSCs). Targeting both cell compartments is necessary to improve prognosis. Here, the authors characterize OAcGD2 ganglioside as a novel GSCs marker that sensitizes chemo‐resistant GSCs to TMZ. The combination of anti‐OAcGD2 monoclonal antibody 8B6 with TMZ results in increased temozolomide genotoxicity and tumor cell death in vitro by enhancing temozolomide tumor uptake. Furthermore, 8B6 works synergistically with TMZ to compromise GSCs self‐renewal. The identification of OAcGD2 as a GSC‐associated antigen offers a novel opportunity for optimizing TMZ chemotherapy in GBM patients to prevent recurrence. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. A "novel" protocol for the analysis of hydroxycinnamic acids in leaf tissue of chicory (Cichorium intybus L., Asteraceae).

Author

Bahri M, Hance P, Grec S, Quillet MC, Trotin F, Hilbert JL, and Hendriks T

Subjects
Asteraceae, Chemistry, Pharmaceutical methods, Chromatography, High Pressure Liquid methods, Chromatography, Liquid methods, Coumaric Acids chemistry, Mass Spectrometry methods, Chemistry, Pharmaceutical trends, Cichorium intybus, Coumaric Acids analysis, Plant Leaves
Abstract

A "novel" protocol is presented for easy and reliable estimation of soluble hydroxycinnamate levels in Cichorium intybus L. leaf tissue in large-scale experiments. Samples were standardized by punching 6 discs per leaf, and hydroxycinnamates were extracted by submerging the discs in 80% ethanol with 5% acetic acid for at least 48 h in the darkness at 4°C. Residual dry mass of the discs was used for a posteriori correction of compound levels. Chlorophyll was eliminated by chloroform, and the aqueous phases were transferred to microplates, dried, and dissolved in 50% methanol for HPLC analysis and storage. An HPLC program of 8 min was developed for the analysis of the extracts. Comparisons with extractions of liquid nitrogen powders indicated that the novel extraction method was reliable. No degradation of the major hydroxycinnamates-caftaric, chlorogenic, and chicoric acids-was observed, during maceration at ambient temperatures, or after storage for 1 year.

Published
2012
Full Text
View/download PDF

18. [Hospital solid waste: quantification. Bacteriological analyses--case of hospital Ibn Sina].

Author

Bahri M, Belkhadir R, Benzakour M, Idrissi L, and Khadri A

Subjects
Drug Resistance, Bacterial, Environmental Monitoring, Humans, Pseudomonas aeruginosa drug effects, Public Health, Risk Factors, Staphylococcus aureus drug effects, Tunisia, Medical Waste Disposal, Pseudomonas aeruginosa isolation & purification, Staphylococcus aureus isolation & purification
Abstract

Hospital waste represent, by their nature and their constitution, a big threat to health in the intra and extra hospital area. and a source of pollution for the environment. A 12-day campaign of weighing of the waste produced by the hospital Ibn Sina of Rabat-Morocco should an average of 1.75 kg/bed/day. In order to identify the hospital pathogenic germs as well as their sensitivities to antibiotics, some bacteriological analyses have been done on the percolat waste of this hospital. The results of these analyses put in evidence the presence of Pseudomonas aeruginosa and Staphylococcus aureus and their resistance to some antibiotics.

Published
2006

19. [Association of systemic lupus erythematosis and myasthenia gravis. A new case report].

Author

Louzir B, Ben Abdelhafidh N, Bahri M, M'Sadek F, Ksontini I, Boussema E, and Othmani S

Subjects
Adrenal Cortex Hormones therapeutic use, Adult, Cyclophosphamide administration & dosage, Cyclophosphamide therapeutic use, Female, Humans, Immunoglobulins, Intravenous therapeutic use, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents therapeutic use, Lupus Erythematosus, Systemic drug therapy, Myasthenia Gravis drug therapy, Myasthenia Gravis pathology, Lupus Erythematosus, Systemic complications, Myasthenia Gravis etiology
Abstract

The association of myasthenia gravis (MG) and systemic lupus erythematosus (SLE) is a quite rare one. We report here one case and try to discuss the physiopathologic mechanisms and also the clinical, evolutive and therapeutic features of this morbid association. It's the case of a woman of 43 years old followed in our department since 1999. The patient has been treated by corticosteroids (prednisone) with monthly administered cyclophospamide pulses. Nine months lately, she develops a diplopia with a ptosis, a dysphagia and a muscular weakness. The treatment was mainly based on intravenous immunoglobulins. The later evolution was favourable. The coexistence of SLE and MG is not casual. It must be considered in every lupic patient developing neuromuscular troubles.

Published
2003

20. [Interpretation of hypertransaminasemia].

Author

Othmani S, Bahri M, and Bahri M

Subjects
Algorithms, Biopsy, Chronic Disease, Decision Trees, Diabetes Mellitus blood, Diabetes Mellitus diagnosis, Fatty Liver blood, Fatty Liver diagnosis, Hepatitis, Viral, Human blood, Hepatitis, Viral, Human diagnosis, Humans, Liver Diseases etiology, Obesity blood, Obesity diagnosis, Predictive Value of Tests, Prognosis, Alanine Transaminase blood, Aspartate Aminotransferases blood, Liver Diseases blood, Liver Diseases diagnosis, Muscular Diseases blood, Muscular Diseases diagnosis
Abstract

Raised serum level of transaminases aspartate (aminotransferase and alanine aminotransferase) is a frequent situation in medical practice. It is considered as moderate when the level is under 10 times normal and as chronic when it lasts for more than 6 months. The most common etiologies for chronically elevated transaminases are alcohol use, viral hepatitis, liver steatosis, diabetes, obesity and medications. Many non invasive tests, including history, physical examination, blood tests (markers for hepatitis A and B, muscular enzymes), and imaging procedures (abdominal ultrasonography) are usually done and lead to a correct diagnosis in 80% of patients. When the diagnosis cannot be determined non invasively a liver biopsy is recommended in order to make diagnosis, to evaluate the prognosis and to start an adapted treatment.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results